Shanghai Haisisenno Pharmaceutical Technology

Shanghai Haisisenno Pharmaceutical Technology is a key subsidiary of Sirnaomics, a clinical-stage biopharmaceutical company specializing in RNA interference (RNAi) therapeutics. Based in Shanghai, the company focuses on the research, development, and CMC (Chemistry, Manufacturing, and Controls) of innovative drugs using its proprietary Polypeptide Nanoparticle (PNP) delivery platform. This technology enables the simultaneous delivery of multiple siRNAs to target specific disease-causing genes, particularly in oncology and fibrosis. The company's lead candidate, STP705, is currently in mid-to-late-stage clinical trials for non-melanoma skin cancer and other fibro-inflammatory diseases. Haisisenno plays a vital role in Sirnaomics' global strategy to develop a diverse pipeline of RNA-based medicines for unmet medical needs.